Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAO/ARO/AIO-12 sequence study in locally advanced rectal cancer
2011-006310-13Phase 2Completed
- Sponsor
- Universitätsklinikum Frankfurt
- Start
- Oct 2014
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of oxaliplatin, fluorouracil and folinic acid in rectal adenocarcinoma and rectal cancer (2 arms), sponsored by Universitätsklinikum Frankfurt. Primary endpoint: Pathological complete remission rate. Started Oct 2014; status: completed.
02
Drugs
oxaliplatinfluorouracilfolinic acid
03
Conditions
rectal adenocarcinomarectal cancer
Beyond the preview
Go deeper on 2011-006310-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006310-13.